Richard P Slaughter Associates Inc Biogen Inc. Transaction History

Richard P Slaughter Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 11, 2022	SELL	$193.77 - $244.14 $597,586 - $752,927	-3,084 Closed	0 $0
Q4 2021 Jan 13, 2022	SELL	$223.92 - $287.77 $338,567 - $435,108	-1,512 Reduced 32.9%	3,084 $739,000
Q3 2021 Oct 06, 2021	BUY	$282.99 - $369.05 $848 - $1,107	3 Added 0.07%	4,596 $1.3 Million
Q2 2021 Jul 12, 2021	SELL	$259.0 - $414.71 $166,537 - $266,658	-643 Reduced 12.28%	4,593 $1.59 Million
Q1 2021 Apr 14, 2021	BUY	$242.95 - $284.63 $396,980 - $465,085	1,634 Added 45.36%	5,236 $1.46 Million
Q4 2020 Jan 20, 2021	SELL	$236.26 - $355.63 $229,408 - $345,316	-971 Reduced 21.23%	3,602 $881,000
Q3 2020 Oct 13, 2020	BUY	$264.77 - $305.71 $79,431 - $91,713	300 Added 7.02%	4,573 $1.3 Million
Q2 2020 Jul 09, 2020	SELL	$258.66 - $342.55 $186,493 - $246,978	-721 Reduced 14.44%	4,273 $1.14 Million
Q1 2020 May 28, 2020	SELL	$268.85 - $341.04 $45,166 - $57,294	-168 Reduced 3.25%	4,994 $1.58 Million
Q4 2019 May 27, 2020	BUY	$220.06 - $304.07 $1.14 Million - $1.57 Million	5,162 New	5,162 $1.53 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Richard P Slaughter Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Richard P Slaughter Associates Inc with notifications on news.